ビーゲン社のPD-1阻害薬ティスレリズマブ、日本で承認取得 グローバル製薬大手に挑む

This approval in Japan, a leading APAC pharmaceutical market, signals a new era for Chinese biotech, validating its innovation and regulatory prowess. It sets a crucial precedent for other APAC biopharmaceutical companies, particularly those in South Korea and Singapore, aiming for market entry into highly regulated developed economies. This could intensify regional competition and foster more cross-border R&D collaborations within Asia.